Jan Diekmann
![Jan Diekmann Jan Diekmann](https://lnp-immunogenicity-toxicity-summit.com/wp-content/uploads/sites/813/2023/08/Untitled-design-150x150.png)
Company: BioNTech
Job title: Senior Director Non-clinical Safety
Seminars:
Preclinical Safety Evaluation of mRNA Cancer Therapeutics: A Platform Approach 2:30 pm
Toxicology assessment of RNA-therapeutics can be split into two parts – assessment of RNA-LNP characteristics and the assessment of translated protein Toxicity data of an RNA-LNP platform facilitating various RNA payloads show a comparable safety profile in non-clinical safety studies Platform-based strategy could reduce the need for toxicity tests involving animal testing (3R)Read more
day: Day One